Novel Quinolizidinyl Derivatives as Antiarrhythmic Agents
摘要:
Eighteen analogues of lidocaine, mexiletine, and procainamide were synthesized, replacing their aminoalkyl chains with the rigid and cumbersome quinolizidine nucleus. The target compounds were tested for antiarrhythmic, inotropic, and chronotropic effects on isolated guinea pig (gp) heart tissues and to assess calcium antagonist activity. Most compounds exhibited from moderate to high antiarrhythmic activity, and compounds 7, 9, and 19 were more active and potent than quinidine and lidocaine, while producing only modest inotropic, chronotropic, and vasorelaxant effects. These compounds were studied on spontaneously beating Langendorff-perfused gp heart. While quinidine and amiodarone produced a dose-dependent prolongation of all the ECG intervals, compounds 7, 9, and 19, even at concentrations 10-20 times higher than EC50 for the antiarrhythmic activity, only moderately prolonged the PR and QT intervals, leaving unchanged the QRS complex. Ether 7 deserves further investigations due to its interesting cardiovascular profile.
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer’s disease
6-hydroxycoumarin an inverted selectivity for acetylcholinesterase (AChE) was observed (e.g. 46: IC50 versus AChE = 0.35 μM; SI = 0.06). Docking studies furnished a sound interpretation of the observed different enzyme activity. Several of the studied compounds have shown, in the past, additional pharmacological properties (as antagonism on presynaptic muscarinic autoreceptor; inhibition of enkephaline aminopeptidase
在强效和选择性丁酰胆碱酯酶(BChE)抑制剂Ethopropazine和Astra1397的模式上,研究了双环和三环(杂)芳族系统的喹喔啉基衍生物对偶或BChE选择性抑制剂。所有化合物均显示出对两种胆碱酯酶的活性,但对BChE的抑制作用通常更强,大多数化合物的亚微摩尔IC 50值(例如15:IC 50 对BChE = 0.15μM; SI = 47)。但是,在6-羟基香豆素的喹唑啉基衍生物的一个子集中,观察到了对乙酰胆碱酯酶(AChE)的反向选择性(例如,46:IC 50 与AChE = 0.35μM; SI = 0.06)。对接研究对观察到的不同酶活性提供了很好的解释。过去,一些研究过的化合物显示出与阿尔茨海默氏病有关的其他药理特性(如对突触前毒蕈碱型自身受体的拮抗作用;对脑啡肽氨基肽酶的抑制作用和抗精神病活性),因此可能代表了一些有趣的疾病的发展热点。单实体多目标药物。
Novel amodiaquine congeners as potent antimalarial agents
To develop new classes of antimalarialagents, the possibility of replacing the phenolic ring of amodiaquine, tebuquine, and isoquine with other aromatic nuclei was investigated. Within a first set of pyrrole analogues, several compounds displayed high activity against both D10 (CQ-S) and W-2 (CQ-R) strains of Plasmodium falciparum. The isoquine structure was also modified by replacing the diethylamino
[EN] PROTEIN KINASE C INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PROTÉINE KINASE C ET UTILISATIONS DE CEUX-CI
申请人:RIGEL PHARMACEUTICALS INC
公开号:WO2014089112A1
公开(公告)日:2014-06-12
This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
issue, the corresponding racemic compound, derived from synthetic (±)-lupinine was considered a cheaper alternative for the development of a novel antimalarial agent. Therefore, the racemic and the 7-chloro-4-(N-(+)-lupinyl)aminoquinoline ((±)-AM-1; (+)-AM-1) were synthesized and their in vitro antimalarial activity and cytotoxicity compared with those of (−)-AM-1. The (+)-lupinine required for the synthesis
Modified Coumarins. 35. Synthesis of Coumarins Containing a Lupinine Moiety
作者:Yu. A. Nikitina、A. I. Galaev、Ya. L. Garazd、M. M. Garazd、V. G. Kartsev
DOI:10.1007/s10600-016-1545-3
日期:2016.1
New coumarin derivatives containing a lupinine moiety were prepared via amidation of coumarinyloxyacetic, coumarinylacetic, and coumarinylpropionic acids by lupinamine.